69 search results for: mechanism of disease
ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden
Professor Henrik Watz explores the complex relationship between inflammation and COPD, highlighting its impact on patients' health and overall quality of life.
ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management
Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, discuss preclinical findings, and review ongoing clinical research targeting IL-33 in COPD.
ADVENT On-Air Podcast: The Multifaceted Patient Burden and Drivers of Disease in Prurigo Nodularis
In this episode, Dr. Sarina Elmariah and Dr. Brian Kim explore prurigo nodularis (PN), with a focus on severe itch, fibrotic skin lesions, and their impact on patients’ quality of life. They discuss PN epidemiology, common comorbidities, and the challenges of managing multimorbid patients, while breaking down the neuroimmune mechanisms, highlighting the role of type 2 cytokines in itch and lesion development.
Spotlight on Type 2 Inflammation in the Upper and Lower Airways
In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.
CRSwNP Triathlon: An Interactive Learning Experience
Embark on this interactive triathlon challenge to uncover the interplay of type 2 inflammation, barrier dysfunction, and neuroimmune dysregulation in the disease pathology of CRSwNP.
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.
ERS 2024 | Perspectives From the Evolving Biologic Landscape in COPD
Professor Alberto Papi presents the latest clinical data on current and emerging biologics for COPD with type 2 inflammation.
ERS 2024 | IL-33 A Promising Target
Professor Klaus Rabe presents the latest clinical data on current and emerging biologic therapies targeting IL-33 in COPD.
Can advanced systemic therapies modify pathomechanisms in AD?
Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.
CLCI in Atopic Dermatitis Infographic
This infographic highlights how uncontrolled moderate‑to‑severe atopic dermatitis (AD) can lead to Cumulative Life Course Impairment (CLCI) by contributing to ongoing physical, psychological, and social burdens such as itch and sleep loss, impaired bone growth and mental health challenges. It emphasizes the importance of early and effective disease control to help reduce long‑term impact on patients.
Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?
Dr. Backer discusses assessing remission in CRSwNP by evaluating the patient's sense of smell in this video clip from the EAACI 2024 symposium.
Lung Function Decline: Why it Matters and What’s at Stake for Patients
Understand the drivers of lung function decline in chronic obstructive pulmonary disease (COPD), including chronic inflammation, key risk factors, and the impact on patient well-being .
